Narrative review discusses perioperative local anesthetics and regional anesthesia in cancer care
Local Anesthetics May Slow Cancer Spread
This narrative review examines the role of perioperative local anesthetics and regional anesthesia compared to opioids within comprehensive …
Using local anesthesia instead of just opioids during surgery might help stop cancer from spreading after the operation.
Subcutaneous amivantamab shows shorter administration time and fewer infusion reactions in advanced solid tumors
Could a simple injection replace hours-long cancer infusions?
A phase Ib clinical trial in 158 patients with advanced solid malignancies evaluated subcutaneous amivantamab administration.
A new injection method for advanced cancer treatment cuts administration time to under 10 minutes and reduces severe side effects compared t…
Research across Cancer
Related studies from across the Cancer family.
cGAS–STING activation correlates with improved survival and enhanced checkpoint blockade response in cancer
Activating a cancer-fighting immune pathway can help tumors shrink but too much may backfire
This narrative review synthesizes evidence on cGAS–STING pathway activation in cancer. The authors report that heightened activity correlate…
Turning on a specific immune pathway helps some cancer patients survive longer, yet overactivating it can cause the immune system to stop wo…
T cell-based therapies show promise but face barriers in solid tumors
CAR-T and TIL therapies face hurdles in treating solid tumors
This narrative review examines CAR-T, TIL, and TCE therapies for hematologic and solid malignancies. Key challenges include on-target/off-tu…
A review notes that CAR-T, TIL, and TCE therapies struggle with tumor microenvironments and manufacturing issues for solid cancers.
Chemoimmunotherapy improves survival in solid tumors regardless of liver metastasis status
Chemoimmunotherapy helps solid tumor patients, with or without liver metastases
This systematic review and meta-analysis evaluated 25915 patients with solid tumors receiving chemoimmunotherapy versus chemotherapy alone. …
For people with solid tumors, adding immunotherapy to chemo helps survival whether or not cancer has spread to the liver.
Cadonilimab plus chemotherapy improves objective response rate to 0.62 in solid tumor patients
Meta-analysis shows cadonilimab plus chemo improves outcomes for solid tumors
This systematic review and meta-analysis evaluated cadonilimab in patients with solid tumors, including gastric cancer and cervical non-smal…
A meta-analysis of 1,359 patients found cadonilimab combined with chemotherapy improved response rates and survival for solid tumors includi…
Review of BsAb-armed T cells for solid tumors and CAR-T and BsAb therapy
BsAb-armed T cells may help solid tumors fight back against cancer
This narrative review synthesizes evidence on BsAb-armed T cells (EATs) for solid tumors, comparing them to CAR-T and BsAb therapy. The auth…
New review suggests BsAb-armed T cells could improve tumor infiltration and reduce immune escape in solid tumors compared to standard CAR-T …
Review of T cell engagers highlights potential for treating solid tumors and small cell lung cancer cases
Review of tarlatamab for solid tumors and small cell lung cancer
This review examines T cell engagers as a promising intervention for solid tumors, specifically small cell lung cancer. Current data suggest…
This review looks at tarlatamab, a T cell engager, for treating solid tumors and small cell lung cancer. It examines how these drugs work.
Narrative review of adoptive cell therapies for solid tumors and their challenges
New Cell Therapy Finally Reaches Stubborn Solid Tumors
This narrative review synthesizes evidence on adoptive cell therapies for solid tumors, including CAR-T, TIL, and TCR-T approaches. The auth…
• Cell therapy now shows real promise against solid cancers like lung or breast • Patients with hard-to-treat tumors may gain new options so…
Review of methionine manipulation in solid tumor immunotherapy settings
Doctors explore changing methionine levels to help immune cells fight solid tumors better
This narrative review examines the role of therapeutic manipulation of methionine availability, GCN2 signaling, and reactive oxygen species …
This review looks at how changing methionine availability might help immune cells work harder against solid tumors. It focuses on specific s…
Meta-analysis finds Type 2 diabetes linked to poorer survival in solid tumor patients on immune checkpoint inhibitors
Patients with diabetes may face worse survival outcomes when treated with certain cancer drugs compared to those without diabetes
This meta-analysis of 1,225 participants with solid tumors treated with immune checkpoint inhibitors found that Type 2 diabetes was associat…
A large review found that people with type 2 diabetes had lower survival rates when using specific cancer medicines. This link was strong in…
Mitochondrial engineering enhances CAR-T cell therapy for solid and blood cancers
New cell therapy upgrade helps immune cells survive longer in tumors
A mini-review explores mitochondrial engineering strategies to boost CAR-T cell efficacy against solid and hematological malignancies, highl…
A new approach to engineering immune cells could solve a major problem: why they stop working inside solid tumors.
Early time-of-day immune checkpoint inhibitor administration improves overall survival in advanced solid tumors
Cancer Patients Live Longer When Immunotherapy Starts Early in Day
This systematic review and meta-analysis evaluated 6129 patients with advanced solid tumors receiving immune checkpoint inhibitors. Earlier …
• Morning immunotherapy shots link to longer survival for advanced cancers • Helps patients fighting lung stomach kidney and other tough can…
FDA Approves Enhertu (fam-trastuzumab deruxtecan-nxki) for Multiple HER2-Positive and HER2-Low Cancers
FDA approves Enhertu for several types of HER2 positive cancers.
FDA approved Enhertu for several indications including HER2-positive metastatic breast cancer, HER2-low and HER2-ultralow breast cancer, HER…
The FDA has approved Enhertu for multiple cancers, including breast, lung, stomach, and other solid tumors that have a specific protein call…